Saad Fred
Université de Montréal, CHUM/Hôpital Notre-Dame, 1560 Sherbrook E, Montreal, Québec H2L 4M1, Canada.
Cancer Treat Rev. 2006;32 Suppl 1:3-6. doi: 10.1016/s0305-7372(06)80002-2.
A reduction in bone turnover activity, assayed by bone markers, appears to correlate with improved outcomes. Thus, use of bone markers to measure abnormal bone turnover may help identify patients at increased risk for bone complications or skeletal-related events (SREs). In addition, bone markers may prove useful in monitoring response to treatment and customising future treatment. Although many questions remain concerning use of bone markers in the treatment of metastatic cancer, these markers are expected to have a valuable role in managing metastatic bone disease (MBD). This review examines SREs and the burden they impose on patients, the relationship between SREs and bone turnover markers, and the potential role of bone markers in guiding treatment and improving patients' quality of life (QOL).
通过骨标志物检测的骨转换活性降低似乎与改善的预后相关。因此，使用骨标志物来测量异常的骨转换可能有助于识别发生骨并发症或骨相关事件（SREs）风险增加的患者。此外，骨标志物可能在监测治疗反应和定制未来治疗方面有用。尽管关于骨标志物在转移性癌症治疗中的应用仍有许多问题，但这些标志物有望在转移性骨病（MBD）的管理中发挥重要作用。本综述探讨了SREs及其给患者带来的负担、SREs与骨转换标志物之间的关系，以及骨标志物在指导治疗和改善患者生活质量（QOL）方面的潜在作用。
